$204.86▼ 0.25 (0.12%)
Real-time prices · US Markets95% of 21 covering analysts have a positive rating.
low return on equity (-79%).
Quality
2
Health
7.7
Growth
3.6
Valuation
4.7
Sentiment
8.9
Analyst Target
$251.21
▲ +22.6% from current
Price Chart
Latest News
- Revolution Medicines Insider Sold Shares Worth $3,153,807, According to a Recent SEC Filing
- Revolution Medicines Gets US FDA Breakthrough Therapy Designation for Rasonque To Treat Pancreatic Cancer
- Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
Fundamentals
Trailing P/E
—
price-to-earnings
Forward P/E
-34.4×
next 12 months est.
Market Cap
$43.9B
market capitalization
Div Yield
—
dividend yield
Profit Margin
0.0%
net profit margin
Gross Margin
0.0%
revenue minus COGS
ROE
-79.1%
return on equity
Beta
1.41
vs S&P 500
52-Week Range
$42 — $224
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
What do analysts say about Revolution Medicines, Inc. right now?
Revolution Medicines, Inc.'s Q·Score is 5/10 (Bearish), reflecting its current fundamentals, analyst data, and valuation metrics. 95% of 21 covering analysts have a positive rating. Key area to monitor: low return on equity (-79%). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for RVMD?
The consensus price target for RVMD is $251.21, based on ratings from 20 Wall Street analysts. This is 22.6% above the current price of $204.86. Price targets are forward-looking estimates and not guarantees of future performance.
Is RVMD overvalued or undervalued?
Revolution Medicines, Inc. (RVMD) scores below peers on valuation metrics, trading above typical sector multiples. The consensus analyst price target of $251.21 is 23% above the current price.
When does Revolution Medicines, Inc. report its next earnings?
Revolution Medicines, Inc.'s next earnings report is expected on approximately November 4, 2026.
What is Revolution Medicines, Inc.'s profit margin?
Revolution Medicines, Inc. has a net profit margin of 0.0%, indicating the company is currently operating at a net loss. Its gross margin stands at 0.0%, reflecting a more cost-intensive business model.
How much debt does Revolution Medicines, Inc. have?
Revolution Medicines, Inc. has a debt-to-equity ratio of 0.46×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 11.38×, indicating comfortable short-term liquidity.